how big is Fredun Pharma?

As of Jun 06, Fredun Pharmaceuticals Ltd has a market capitalization of 348.00 Cr, classifying it as a Micro Cap company, with recent net sales of 403.48 Cr and a net profit of 18.79 Cr over the last four quarters.

Market Cap: As of Jun 06, Fredun Pharmaceuticals Ltd has a market capitalization of 348.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 403.48 Cr. The sum of Net Profit for the same period is 18.79 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is based on Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 121.47 Cr, while the Total Assets amount to 307.60 Cr.

What does Fredun Pharma do?

Fredun Pharmaceuticals Ltd, a Micro Cap company established in 1987, operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 102 Cr and a net profit of 5 Cr for December 2024. The company has a market cap of Rs 345 Cr and key metrics include a P/E of 18.00 and a dividend yield of 0.10%.

Overview: <BR>Fredun Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals was converted into a public limited company in March 1994. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 102 Cr (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: 5 Cr (Quarterly Results - Dec 2024) <BR>Market-cap value: Rs 345 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.10% <BR>Debt-Equity: 0.85 <BR>Return on Equity: 15.47% <BR>Price-to-Book: 2.85 <BR><BR>Contact Details: <BR>Address: 26 Manoj Industrial Premises, G D Ambedkar Marg Wadala Mumbai Maharashtra : 400031 <BR>Tel: 91-22-40318111 <BR>Email: business@fredungroup.com <BR>Website: http://www.fredungroup.com

Has Fredun Pharma declared dividend?

Yes, Fredun Pharmaceuticals Ltd has declared a 7% dividend, with an ex-date of September 23, 2024. While recent total returns have been negative over shorter periods, the company has shown significant positive returns over the longer term.

Fredun Pharmaceuticals Ltd has declared a 7% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 7%<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -5.58%, with a dividend return of 0%, resulting in a total return of -5.58%.<BR><BR>Over the past year, the price return was -8.86%, the dividend return was 0.09%, leading to a total return of -8.77%.<BR><BR>In the 2-year period, the price return was -12.9%, with a dividend return of 0.16%, culminating in a total return of -12.74%.<BR><BR>For the 3-year period, the price return was -14.32%, the dividend return was 0.18%, resulting in a total return of -14.14%.<BR><BR>In the last 4 years, the price return was 71.47%, with a dividend return of 0.51%, giving a total return of 71.98%.<BR><BR>Over the past 5 years, the price return was 296.33%, and the dividend return was 1.12%, leading to a total return of 297.45%.<BR><BR>Overall, while Fredun Pharma has declared a dividend, the total returns over various periods show a mix of negative returns in the shorter terms and significant positive returns in the longer terms, indicating volatility and potential recovery in the company's performance.

Who are the peers of the Fredun Pharma?

Fredun Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Oxygenta Pharma, Trident Lifeline, Gennex Lab, and Sanjiv Parant. Fredun Pharma has average management risk and growth, with a below-average capital structure, while its 1-year return is -8.70%.

Peers: The peers of Fredun Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Oxygenta Pharma, Trident Lifeline, Gennex Lab., and Sanjiv.Parant.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Torrent Pharma, and Sanjiv.Parant., while Average management risk is found at Fredun Pharma and Trident Lifeline. Below Average management risk is noted for Gennex Lab. and Ambalal Sarabhai. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Trident Lifeline, and Sanjiv.Parant., while Good growth is seen at Fredun Pharma and Gennex Lab. Below Average growth is reported for Divi's Lab. and Torrent Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma and Trident Lifeline. Fredun Pharma has a Below Average capital structure, and Oxygenta Pharma does not qualify.<BR><BR>Return Snapshot: Oxygenta Pharma has the highest 1-year return at 169.57%, while Gennex Lab. has the lowest at -22.86%. Fredun Pharma's 1-year return is -8.70%, which is higher than Gennex Lab.'s but lower than Oxygenta Pharma's. Additionally, the six-month return is negative for Fredun Pharma, Gennex Lab., and Ambalal Sarabhai.

What is the technical trend for Fredun Pharma?

As of April 15, 2025, Fredun Pharma's technical trend is mildly bearish, with weekly indicators showing some positive momentum while daily moving averages and monthly indicators remain bearish.

As of 15 April 2025, the technical trend for Fredun Pharma has changed from bearish to mildly bearish. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the monthly indicators remain bearish. The daily moving averages indicate a mildly bearish stance, which is a counterpoint to the weekly signals. The Bollinger Bands show a mildly bullish trend on the weekly timeframe but are bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this outlook.

Who are in the management team of Fredun Pharma?

As of March 2022, the management team of Fredun Pharma includes Daulat N Medhora (Chairperson & Joint Managing Director), Nariman B Medhora (Executive Director), Fredun N Medhora (Managing Director & CFO), and several independent directors, along with a Company Secretary. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Fredun Pharma includes the following individuals:<BR><BR>1. Daulat N Medhora - Chairperson & Joint Managing Director<BR>2. Nariman B Medhora - Executive Director<BR>3. Aspi N Raimalwala - Non-Executive & Independent Director<BR>4. Fredun N Medhora - Managing Director & Chief Financial Officer<BR>5. Rohinton Kanga - Non-Executive & Independent Director<BR>6. Jinkal Shah - Company Secretary & Compliance Officer<BR>7. Daisy Dsouza - Additional Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the top shareholders of the Fredun Pharma?

The top shareholders of Fredun Pharma are Daulat Nariman Medhora with 29.88%, followed by Nikhil Kishorchandra Vora at 6.38%. Individual investors collectively own 44.5%, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Fredun Pharma include Daulat Nariman Medhora, who holds the largest stake at 29.88%. Following him, the highest public shareholder is Nikhil Kishorchandra Vora, with a holding of 6.38%. Additionally, individual investors collectively own 44.5% of the company. There are no institutional holdings or pledged promoter shares reported.

When is the next results date for Fredun Pharma?

The next results date for Fredun Pharma is 08 November 2025.

The next results date for Fredun Pharma is scheduled for 08 November 2025.

Are Fredun Pharma latest results good or bad?

Fredun Pharmaceuticals' latest results show a net profit increase of 12.83% to ₹6.77 crores, indicating improved profitability, but revenue fell sharply by 28.41% to ₹119.85 crores, raising concerns about demand sustainability. While operational efficiency improved with a higher operating margin, the significant revenue decline warrants caution for investors.

Fredun Pharmaceuticals' latest results present a mixed picture. On one hand, the company reported a net profit of ₹6.77 crores for Q2 FY26, which is a positive increase of 12.83% quarter-on-quarter. This indicates that the company has managed to improve its profitability despite facing challenges.<BR><BR>However, the revenue for the same quarter saw a significant decline of 28.41%, dropping to ₹119.85 crores from ₹167.41 crores in the previous quarter. This sharp drop raises concerns about demand sustainability and the visibility of future orders. <BR><BR>Despite the revenue contraction, the company demonstrated strong operational efficiency, as evidenced by an increase in operating margin to 14.23%, up from 10.43% in the prior quarter. This improvement in margins suggests that Fredun Pharmaceuticals is effectively managing costs and optimizing its product mix.<BR><BR>In summary, while the net profit growth is a positive sign, the substantial revenue decline is a cause for caution. Investors should keep an eye on future quarters to see if the revenue drop is a temporary issue or indicative of deeper challenges.

Is Fredun Pharma overvalued or undervalued?

As of November 10, 2025, Fredun Pharma is considered overvalued with a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%, despite outperforming the Sensex with a year-to-date return of 120.94%.

As of 10 November 2025, Fredun Pharma's valuation grade has moved from attractive to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%. <BR><BR>In comparison to its peers, Fredun Pharma's PE ratio is lower than Sun Pharma's 35.15 but significantly higher than Cipla's 22.45, suggesting that while it is less expensive than some competitors, it remains on the higher end of the spectrum. Additionally, the company's recent stock performance has outpaced the Sensex, with a year-to-date return of 120.94% compared to the Sensex's 6.91%, reinforcing the notion of overvaluation amidst strong market enthusiasm.

Should I buy, sell or hold Fredun Pharma?

How has been the historical performance of Fredun Pharma?

Fredun Pharma has shown steady growth, with net sales of 456.27 crore and a profit after tax of 19.74 crore for the fiscal year ending March 2025. The company's total assets increased to 307.60 crore, reflecting a solid financial position and consistent growth in sales and profits.

Answer:<BR>The historical performance of Fredun Pharma reflects a steady growth trajectory in various financial metrics.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Fredun Pharma reported net sales of 456.27 crore, resulting in a total operating income of the same amount. The total expenditure, excluding depreciation, was 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore, which corresponds to an operating profit margin of 12.16%. The profit before tax stood at 27.49 crore, with a profit after tax of 19.74 crore, yielding a PAT margin of 4.37%. The earnings per share (EPS) were reported at 41.82, while the diluted EPS was slightly higher at 44.83. On the balance sheet, total assets increased to 307.60 crore in March 2024 from 257.28 crore in the previous year, with total liabilities also rising to 105.51 crore. The book value per share adjusted to 255.15, indicating a solid increase from prior years. Cash flow analysis shows a net cash outflow of 2.00 crore for March 2024, with cash and cash equivalents closing at 1.00 crore. Overall, Fredun Pharma demonstrates a robust financial position with consistent growth in sales, profits, and asset values over the years.

Why is Fredun Pharma falling/rising?

As of 20-Dec, Fredun Pharmaceuticals Ltd's stock price is rising to 1,631.65, reflecting a recovery in investor sentiment after recent declines. Despite concerns over reduced investor participation, strong long-term growth and significant net profit increases support the stock's upward trend.

As of 20-Dec, Fredun Pharmaceuticals Ltd's stock price is rising, currently at 1,631.65, with a change of 6.25 (0.38%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline, indicating a potential recovery in investor sentiment. Additionally, the stock opened with a gain of 2% today and reached an intraday high of Rs 1,674.95, reflecting positive trading activity.<BR><BR>Despite a recent underperformance against its sector by -0.37%, the stock has demonstrated strong long-term growth, with net sales increasing at an annual rate of 39.73% and operating profit growing at 55.03%. The company reported a significant net profit growth of 127.87% in its latest results, which has been consistent over the last six quarters. Furthermore, the stock has generated a remarkable return of 116.60% over the past year, significantly outperforming the market's average return of 3.86%.<BR><BR>However, it is important to note that there are some concerns regarding investor participation, as delivery volume has fallen by -45.6% against the five-day average, which may indicate a decrease in investor confidence. Nonetheless, the overall positive financial performance and the stock's attractive valuation compared to its peers contribute to its rising price.

Which are the latest news on Fredun Pharma?